Mylan gets FDA OK for generic Metaglip

April 13 (Reuters) - Mylan Laboratories Inc. MYL.N said its Mylan Pharmaceuticals Inc. unit received U.S. regulatory approval for its generic version of Bristol-Myers Squibb's (BMY.N) diabetes drug Metaglip.

Mylan got marketing approval from the U.S. Food and Drug Administration for Glipizide and Metformin Hydrochloride Tablets in 2.5 mg/250 mg, 2.5 mg/500 mg and 5 mg/500 mg strengths. The product will be shipped immediately, the company said in a statement.

(Reporting by Ankur Relia in Bangalore)

((Editing by Gopakumar Warrier; Reuters Messaging: ankur.relia.reuters.com@reuters.net; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800)) Keywords: MYLAN FDA/

(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nWNAS6270